clinical trial · NCT03777176
A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
Zealand Pharma·phase3·completed·n = 32
Congenital HyperinsulinismDasiglucagonStandard of Care
brief summary
The objective of the trial is to evaluate the efficacy and safety of dasiglucagon administered as a subcutaneous (SC) infusion in reducing hypoglycemia in children with CHI.
started
Feb 7, 2019
primary completion
Aug 31, 2020
completion
Oct 5, 2020
last updated
Dec 13, 2023
official title
A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol